{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.3.3', 'Secondary Variables', 'The secondary variables are progression-free survival (PFS) determined by a Central', 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall survival', '(OS) in randomized set population. Change in patient reported outcome (PRO) with', 'physical functioning as measured by European Organization for Research and Treatment', 'of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) in randomized set', 'population is also a secondary endpoint in this study.', '5.3.3.4', 'Exploratory Variables', 'The exploratory variables are progression-free survival (PFS) based on investigator', 'assessment, objective response rate (ORR) per the CRAC and investigator assessment,', 'respectively, clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, and the duration of response (DOR) per the CRAC and investigator', 'assessment, respectively. Response assessment will be based on RECIST v1.1. Changes', 'in patient reported outcomes (PROs) as measured by EQ-5D-5L and all other PRO', 'domains (except for physical functioning) as measured by European Organization for', 'Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)', 'and Lung Cancer Module (QLQ-LC13) are also exploratory endpoints in this study.', '5.3.4', 'Safety Variables', 'AbbVie will assess adverse events, laboratory data, ECGs and vital signs throughout the', 'study. Adverse events intensity and laboratory evaluation changes will be assessed by', 'utilizing NCI CTCAE Version 4.0. 11', 'During the conduct of the study, the AbbVie medical and safety team will be monitoring', 'blinded, subject laboratory results and serious adverse event data as they are reported.', 'Safety endpoints will be summarized using data from the Safety set. Safety analyses will', 'involve examination of the incidence, severity, and type of treatment-emergent adverse', 'events (TEAEs) reported, changes in vital signs and laboratory test results from baseline', '(the assessment prior to first dose) to specified time points throughout the study.', '60']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.5', 'Pharmacokinetic Variables', 'Serum concentrations of rovalpituzumab tesirine ADC as well as the timing and incidence', 'of ATAs will be tabulated and summarized.', '5.3.6', 'Biomarker and/or Optional Exploratory Research Variables', 'Biomarker Research Variables', 'Blood, serosal fluid, and tumor material samples will be collected to conduct analyses to', 'investigate biomarkers. The types of biomarkers to be analyzed may include, but are not', 'limited to, nucleic acids, proteins, lipids or metabolites.', 'Tumor specimen and CTCs will be tested for DLL3 expression and analyses will be', 'performed to correlate the expression levels to rovalpituzumab tesirine response.', 'Enumeration of CTCs, soluble DLL3 in plasma, or markers that are related to the disease', 'or to drug response will be measured at baseline and post-treatment. The information', 'learned from analyzing these samples may be used to investigate factors influencing', 'response to treatment, pharmacodynamics, PK, safety, scientific questions related to', 'SCLC, and/or in the development of new therapies and diagnostic tests. The results of', 'biomarker testing may not be included with the study summary.', 'Whole blood for pharmacogenetic analysis may include but not be limited to DLL3,', 'ASCL1, or NEUROD1.', 'Exploratory Research Variables', 'Optional samples may be collected to conduct exploratory investigations into known and', 'novel biomarkers. The types of biomarkers to be analyzed may include, but are not', 'limited to, nucleic acids, proteins, lipids or metabolites. The samples may be analyzed as', \"part of a multi-study assessment of factors influencing the subjects' response to the\", 'blinded investigational product (or drugs of the same or similar class) or the development', \"and progression of the subjects' disease or related conditions. The samples may also be\", '61']\n\n###\n\n", "completion": "END"}